The therapeutic potential of the cannabinoids in neuroprotection

Bibliography

• ADAMS R: Marihuana. Harvey Lectures (1942) 37:168–197.
   Google Scholar
• GAONI Y, MECHOULAM R: Isolation, structure and partial synthesis of an active constituent of hashish. I Am. Chem. Soc. (1964) 86:1646–1647.
   Web of Science ®Google Scholar
• MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561–564.
   PubMed Web of Science ®Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61–65.
   PubMed Web of Science ®Google Scholar
• GRUNDY RI, RABUFFETTI M, BELTRAMO M: Cannabinoids and neuroprotection. MM. Neurobiol (2001) 24:29–51.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of the cannabinoids andtheir modes of action in relation to neuroprotection.
   Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
   PubMed Web of Science ®Google Scholar
• PORTER AC, SAUER JM, KNIERMAN MD et al.: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Pharmacol Exp. Ther. (2002) 301:1020–1024.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG: Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. (1999) 6\(Suppl. 3):12–15.
   Google Scholar
• PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert. Opin. Investig. Drugs (2000) 9:1553–1571.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of the pharmacology ofthe cannabinoids and their potential in drug discovery.
   Google Scholar
• HERKENHAM M, LYNN AB, LITTLE MD et al.: Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA (1990) 87:1932–1936.
   PubMed Web of Science ®Google Scholar
• HERKENHAM M, LYNN AB, JOHNSON MR, MELVIN LS, DE COSTA BR, RICE KC: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Neurosci. (1991) 11:563–583.
   PubMed Web of Science ®Google Scholar
• HERKENHAM M, LYNN AB, DE COSTA BR, RICHFIELD EK: Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. (1991) 547:267–274.
   PubMed Web of Science ®Google Scholar
• TSOU K, BROWN S, SANUDO-PENA MC, MACKIE K, WALKER JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience (1998) 83:393–411.
   PubMed Web of Science ®Google Scholar
• FARQUHAR-SMITH WP, EGERTOVA M, BRADBURY EJ, MCMAHON SB, RICE AS, ELPHICK MR: Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell Neurosci. (2000) 15:510–521.
   PubMed Web of Science ®Google Scholar
• CROCI T, MANARA L, AUREGGI G et al.: Li vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. Pharmacol. (1998) 125:1393–1395.
   PubMed Web of Science ®Google Scholar
• GALIEGUE S, MARY S, MARCHAND J et al.: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Ear: Biochem. (1995) 232:54–61.
   PubMedGoogle Scholar
• GERARD CM, MOLLEREAU C, VASSART G, PARMENTIER M: Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. (1991) 279:129–134.
   Web of Science ®Google Scholar
• HOWLETT AC, QUALY JM, KHACHATRIAN LL: Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. (1986) 29:307–313.
   PubMed Web of Science ®Google Scholar
• BOUABOULA M, POINOT-CHAZEL C, BOURRIE B et al.: Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. (1995) 312:637–641.
   Web of Science ®Google Scholar
• RUEDA D, GALVE-ROPERH I, HARO A, GUZMAN M: The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. (2000) 58:814–820.
   PubMed Web of Science ®Google Scholar
• MACKIE K, LAI Y, WESTENBROEK R, MITCHELL R: Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. I Neurosci. (1995) 15:6552–6561.
   Google Scholar
• DEADWYLER SA, HAMPSON RE, MU J, WHYTE A, CHILDERS S: Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. Pharmacol. Exp. Ther. (1995) 2073:734–743.
   Google Scholar
• MACKIE K, HILLE B: Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Nati Acad. Sci. USA (1992) 89:3825–3829.
   PubMed Web of Science ®Google Scholar
• GEBREMEDHIN D, LANGE AR, CAMPBELL WB, HILLARD CJ, HARDER DR: Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. Physiol. (1999) 276:H2085–H2093
   PubMed Web of Science ®Google Scholar
• GERDEMAN G, LOVINGER DM: CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. Neurophysiol. (2001) 85:468–471.
   PubMed Web of Science ®Google Scholar
• SZABO B, WALLMICHRATH I, MATHONIA P, PFREUNDTNER C: Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience (2000) 97:89–97.
   PubMed Web of Science ®Google Scholar
• AUCLAIR N, OTANI S, SOUBRIE P, CREPEL F: Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. j Neurophysiol. (2000) 83:3287–3293.
   PubMed Web of Science ®Google Scholar
• MOLINA-HOLGADO F, LLEDO A, GUAZA C: Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotwdn in astrocytes. Neuroreport (1997) 8:1929–1933.
   PubMed Web of Science ®Google Scholar
• WAKSMAN Y, OLSON JM, CARLISLE SJ, CABRAL GA: The central cannabinoid receptor (CBI) mediates inhibition of nitric oxide production by rat microglial cells. Pharmacol. Exp. Ther. (1999) 288:1357–1366.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ, MUTHIAN S, KEARN CS: Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. (1999) 459, 277–281.
   PubMed Web of Science ®Google Scholar
• KLEIN TW, NEWTON C, FRIEDMAN H: Cannabinoid receptors and immunity. Immunol. Today (1998) 19:373–381.
   PubMedGoogle Scholar
• KLEIN TW, LANE B, NEWTON CA, FRIEDMAN H: The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. (2000) 225:1–8.
   PubMed Web of Science ®Google Scholar
• SMITH SR, TERMINELLI C, DENHARDT G: Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. Pharmacol. Exp. Ther. (2000) 293:136–150.
   PubMed Web of Science ®Google Scholar
• GRUOL DL, SWEENEY DD, CONROY SM, TROTTER C, NETZEBAND JG, QIU Z: Cannabinoids alter neurotoxicity produced by interleukin-6 in central nervous system neurons. Adv. Exp. Med. Biol. (1998) 437:231–240.
   PubMed Web of Science ®Google Scholar
• PUFFENBARGER RA, BOOTHE AC, CABRAL GA: Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Clia (2000) 29:58–69.
   Google Scholar
• JBILO 0, DEROCQ JM, SEGUI M, LE FUR G, CASELLAS P: Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60. FEBS Lett. (1999) 448:273–277.
   PubMed Web of Science ®Google Scholar
• SACERDOTE P, MASSI P, PANERAI AE, PAROLARO D: In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. Neuroimmunol. (2000) 109:155–163.
   PubMed Web of Science ®Google Scholar
• NEWTON C, KLEIN T, FRIEDMAN H: The role of macrophages in THC-induced alteration of the cytokine network. Adv. Exp. Med. Biol. (1998) 437:207–214.
   PubMed Web of Science ®Google Scholar
• BAINS JS, SHAW CA: Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Bradt Res. Brazil Res. Rev. (1997) 25:335–358.
   PubMed Web of Science ®Google Scholar
• ESHHAR N, STRIEM S, KOHEN R, TIROSH 0, BIEGON A: Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Ear: J. Pharmacol. (1995) 283:19–29.
   Google Scholar
• HAMPSON AJ, GRIMALDI M, AXELROD J, WINK D: Cannabidiol and Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Nati Acad. Sri. USA (1998) 95:8268–8273.
   PubMed Web of Science ®Google Scholar
• MARSICANO G, MOOSMANN B, HERMANN H, LUTZ B, BEHLT C: Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. I Neurochem. (2002) 80:448–456.
   PubMed Web of Science ®Google Scholar
• DOBLE A: The role of excitotoxicity in neurodegenerative disease: implications for therapy. Phannacol Ther. (1999) 81:163–221.
   Web of Science ®Google Scholar
• ESHHAR N, STRIEM S, BIEGON A: HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport (1993) 5:237–240.
   PubMed Web of Science ®Google Scholar
• NADLER V, MECHOULAM R, SOKOLOVSKY M: The non-psychotropic cannabinoid(3S,4S)-7-hydroxy-delta 6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci. Lett. (1993) 162:43–45.
   PubMed Web of Science ®Google Scholar
• SKAPER SD, BURIANI A, DAL TOSO R et al.: The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sd. USA (1996) 93:3984–3989.
   Google Scholar
• SHEN M, THAYER SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol (1998) 54:459–462.
   PubMed Web of Science ®Google Scholar
• ABOOD ME, RIZVI G, SALLAPUDI N, MCALLISTER SD: Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. (2001) 309:197–201.
   PubMed Web of Science ®Google Scholar
• HANSEN HH, SCHMID PC, BITTIGAU P et al.: Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. Neurochem. (2001) 78:1415–1427.
   PubMed Web of Science ®Google Scholar
• VAN DER STELT M, VELDHUIS WB, BAR PR, VELDINK GA, VLIEGENTHART JF, NICOLAY K: Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. Neurosci. (2001) 21:6475–6479.
   PubMed Web of Science ®Google Scholar
• VAN DER STELT M, VELDHUIS WB, VAN HAAFTEN GW et al: Exogenous anandamide protects rat brain against acute neuronal injury in vivo. Neurosci. (2001) 21:8765–8771.
   PubMed Web of Science ®Google Scholar
• •First account of protective effects of an endocannabinoid in an in vivo model of acute neuronal injury.
   Google Scholar
• NAGAYAMA T, SINOR AD, SIMON RP et al: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. NeuroscL (1999) 19:2987–2995.
   PubMed Web of Science ®Google Scholar
• •Exhaustive account of the protective effects of WIN55212–2 in several in vitro and in vivo models relevent to cerebral ischaemia.
   Google Scholar
• SINOR AD, IRVIN SM, GREENBERG DA: Endocannabinoids protect cerebral cortical neurons from M vitro ischemia in rats. Neurosci. Lett. (2000) 278:157–160.
   PubMed Web of Science ®Google Scholar
• VERED M, BAR-JOSEPH A, BELAYEV L, BERKOVICH Y, BIEGON A: Anti-ischemia activity of HU-211, a non-psychotropic synthetic cannabinoid. Acta Neurochic Suppl (Wien) (1994) 60:335–337.
   PubMedGoogle Scholar
• BAR-JOSEPH A, BERKOVITCH Y, ADAMCHIK J, BIEGON A: Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol Chem. Neuropathol (1994) 23:125–135.
   PubMedGoogle Scholar
• BELAYEV L, BUSTO R, ZHAO W, GINSBERG MD: HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke (1995) 26:2313–2319.
   PubMed Web of Science ®Google Scholar
• BELAYEV L, BAR-JOSEPH A, ADAMCHIK J, BIEGON A: HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Ma Chem. Neuropathol (1995) 25:19–33.
   PubMedGoogle Scholar
• LEKER RR, SHOHAMI E, ABRAMSKY 0, OVADIA H: Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. Nemo]. ScL (1999) 162:114–119.
   PubMed Web of Science ®Google Scholar
• LOUW DF, YANG FW, SUTHERLAND GR: The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. (2000) 857:183–187.
   PubMed Web of Science ®Google Scholar
• MAULER F, MITTENDORF J, HORVATH E, DE VRYJ: Characterization of the diarylether sulfonylester ( ) (R) 3 (2 Hydroxymethylindany1-4-oxy)pheny1-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. Pharmacol Exp. Ther. (2002) 302:359–368.
   PubMed Web of Science ®Google Scholar
• IADECOLA C, ALEXANDER M: Cerebral ischemia and inflammation. Carr: Opin. Nemo]. (2001) 14:89–94.
   PubMed Web of Science ®Google Scholar
• SHOHAMI E, NOVIKOV M, MECHOULAM R: A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. j Neurotrauma (1993) 10:109–119.
   PubMed Web of Science ®Google Scholar
• SHOHAMI E, GALLILY R, MECHOULAM R, BASS R, BEN-HUR T: Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Neuroimmunol (1997) 72:169–177.
   PubMed Web of Science ®Google Scholar
• NADLER V, BIEGON A, BEIT-YANNAI E, ADAMCHIK J, SHOHAMI E: 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brant Res. (1995) 685:1–11.
   PubMed Web of Science ®Google Scholar
• PANIKASHVILI D, SIMEONIDOU C, BEN-SHABAT S et al.: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 413:527–531.
   PubMed Web of Science ®Google Scholar
• PETRO DJ, ELLENBERGER CJ: Treatment of human spasticity with delta 9-tetrahydrocannabinol. I Clin. Pharmacol (1981) 21:413S–416S.
   Google Scholar
• CLIFFORD DB: Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol (1983) 13:669–671.
   PubMed Web of Science ®Google Scholar
• MARTYN CN, ILLIS LS, THOM J: Nabilone in the treatment of multiple sclerosis. Lancet (1995) 345:579.
   PubMed Web of Science ®Google Scholar
• MOLINA-HOLGADO F, MOLINA-HOLGADO E, GUAZA C: The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. (1998) 433:139–142.
   PubMed Web of Science ®Google Scholar
• WIRGUIN I, MECHOULAM R, BREUER A, SCHEZEN E, WEIDENFELD J, BRENNER T: Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1994) 28:209–214.
   PubMed Web of Science ®Google Scholar
• LYMAN WD, SONETT JR, BROSNAN CE ELKIN R, BORNSTEIN MB: Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. I Neuroimmunol (1989) 23:73–81.
   PubMed Web of Science ®Google Scholar
• ACHIRON A, MIRON S, LAVIE V, MARGALIT R, BIEGON A: Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. Neuroimmunol (2000) 102:26–31.
   PubMed Web of Science ®Google Scholar
• BAKER D, PRYCE G, CROXFORD JL et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84–87.
   PubMed Web of Science ®Google Scholar
• •Detailed account of effects of CB1 and CB2 agonist in a mouse model of multiple sclerosis.
   Google Scholar
• BAKER D, PRYCE G, CROXFORD JL et al.: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB (2001) 15:300–302.
   PubMed Web of Science ®Google Scholar
• CADOGAN AK, ALEXANDER SP, BOYD EA, KENDALL DA: Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochein. (1997) 69:1131–1137.
   PubMed Web of Science ®Google Scholar
• MESCHLER JP, HOWLETT AC, MADRAS BK: Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Ben) (2001) 156:79–85.
   PubMed Web of Science ®Google Scholar
• SILVERDALE MA, MCGUIRE S, MCINNES A, CROSSMAN AR, BROTCHIE JM: Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol (2001) 169:400–406.
   PubMed Web of Science ®Google Scholar
• LASTRES-BECKER I, CEBEIRA M, DE CEBALLOS ML et al.: Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. Neurosci. (2001) 14:1827–1832.
   Google Scholar
• DI MARZO V, HILL MP, BISOGNO T, CROSSMAN AR, BROTCHIE JM: Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB (2000) 14:1432–1438.
   PubMed Web of Science ®Google Scholar
• SIERADZAN KA, FOX SH, HILL M, DICK JP, CROSSMAN AR, BROTCHIE JM: Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 57:2108–2111.
   PubMed Web of Science ®Google Scholar
• GLASS M: The role of cannabinoids in neurodegenerative diseases. Frog. Neuropsychopharinacol Biol. Psychiatry (2001) 25:743–765.
   PubMed Web of Science ®Google Scholar
• RICHFIELD EK, HERKENHAM M: Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. (1994) 36:577–584.
   PubMed Web of Science ®Google Scholar
• GLASS M, DRAGUNOW M, FAULL RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience (2000) 97:505–519.
   PubMed Web of Science ®Google Scholar
• DENOVAN-WRIGHT EM, ROBERTSON HA: Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience (2000) 98:705–713.
   PubMed Web of Science ®Google Scholar
• LASTRES-BECKER I, BERRENDERO F, LUCAS JJ et al.: Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB(1) receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. (2002) 929:236–242.
   PubMed Web of Science ®Google Scholar
• PAGE KJ, BESRET L, JAIN M, MONAGHAN EM, DUNNETT SB, EVERITT BJ: Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and muopioid receptor binding in the basal ganglia. Exp. Brain Res. (2000) 130:142–150.
   PubMed Web of Science ®Google Scholar
• LASTRES-BECKER I, FEZZA F, CEBEIRA M et al.: Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport (2001) 12:2125–2129.
   PubMed Web of Science ®Google Scholar
• LASTRES-BECKER I, HANSEN HH, BERRENDERO F: Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse (2002) 44:23–35.
   PubMed Web of Science ®Google Scholar
• GROTTA J: Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke (2002) 33:306–307.
   PubMed Web of Science ®Google Scholar
• LEES KR: Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke (2002) 33:308–309.
   PubMed Web of Science ®Google Scholar
• LEGOS JJ, TUMA RF, BARONE FC: Pharmacological interventions for stroke: failures and future. Expert. Opin. Investig. Drugs (2002) 11:603–614.
   PubMed Web of Science ®Google Scholar
• FEIGENBAUM JJ, BERGMANN F, RICHMOND SA et al.: Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Nati Acad. Sci. USA (1989) 86:9584–9587.
   PubMed Web of Science ®Google Scholar
• BREWSTER ME, POP E, FOLTZ RL et al: Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int. .1. Clin. Pharinacol The]: (1997) 35:361–365.
   Google Scholar
• PHARMOS CORP: Pharmos corporation reports 2002 first quarter results (2 May 2002):Press Release.
   Google Scholar
• PHARMOS CORP: Pharmos reports significant brain recovery in stroke models using dexanabinol - new dexanabinol analogs seen as powerful neuroprotectants (7 July 2000) Press release.
   Google Scholar
• GW PHARMACEUTICALS PLC: Annual report and accounts for the year ended 30 September 2001 (30 September 2001) Annual report.
   Google Scholar
• BAYER AG: Drug development pipeline: New projects in development at Bayer (1 February 2002):Company communication.
   Google Scholar
• KEARN CS, HILLARD CJ: Rat microglial cells express the peripheral type cannabinoid receptor (CB2) which is negatively coupled to adenylate cyclase. International Cannabinoid Research Society (1997) Abstract.
   Google Scholar
• BREIVOGEL CS, GRIFFIN G, DI MARZO V, MARTIN BR: Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Ma Phannacol (2001) 60:155–163.
   Google Scholar
• •Evidence for the existence of a novel cannabinoid receptor.
   Google Scholar
• JARAI Z, WAGNER JA, VARGA K et al.: Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA (1999) 96:14136–14141.
   PubMed Web of Science ®Google Scholar
• •Evidence for the existence of a novel cannabinoid receptor.
   Google Scholar
• HAJOS N, LEDENT C, FREUND TF: Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience (2001) 106:1–4.
   PubMed Web of Science ®Google Scholar
• •Evidence for the existence of a novel cannabinoid receptor.
   Google Scholar